Omalizumab for Chronic Urticaria: A Case Series and Overview of the Literature

Ivyanskiy, Ilya; Sand, Carsten; Thomsen, Simon Francis

doi:10.1159/000336205

Cited by 42 publications

(26 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many case reports have already shown the beneficial effect of omalizumab in patients with recalcitrant physical urticaria [4, 21, 22, 25]. In addition to previously published reports, our case suggests that omalizumab may be an effective, rapid and safe treatment option in patients with cold contact urticaria who do not sufficiently respond to standard therapy as recommended by existing guidelines.…”

Section: Discussionsupporting

confidence: 69%

Treatment of Severe Cold Contact Urticaria with Omalizumab: Case Reports

Brodská¹,

Schmid‐Grendelmeier²

2012

Case Rep Dermatol

View full text Add to dashboard Cite

We report 2 patients with cold urticaria with different response to treatment with omalizumab (Xolair®). Cold contact urticaria (CCU) is a common subtype of physical urticaria. It is characterized by the development of wheal and/or angioedema within minutes after cold contact. Clinical manifestation of CCU can range from mild, localized whealing to life-threatening anaphylactic shock reactions. Omalizumab has been described to be useful in cases of chronic urticaria and may be an interesting option for treatment of CCU. We describe one patient with significant and long-lasting improvement of symptoms and one without any improvement after anti-immunoglobulin E therapy. In our case reports, we want to highlight that there is still a small group of patients without benefit from omalizumab treatment. It is necessary to identify this minor subgroup of patients where omalizumab does not represent an effective treatment possibility.

show abstract

Section: Discussionsupporting

confidence: 69%

Treatment of Severe Cold Contact Urticaria with Omalizumab: Case Reports

Brodská¹,

Schmid‐Grendelmeier²

2012

Case Rep Dermatol

View full text Add to dashboard Cite

show abstract

“…: In randomized trials, side-effects reported in more that 3% of patients receiving consisted in headache, diarrhoea, joint pain, dysmenorrhoea and upper respiratory tract infections, without differences between the groups receiving active treatment and placebo [103]. …”

Section: Resultsmentioning

confidence: 99%

Management of urticaria: not too complicated, not too simple

Ferrer

Bartra

Giménez‐Arnau

et al. 2015

Clin Experimental Allergy

View full text Add to dashboard Cite

In spite of being an old disease and apparently easy to diagnose, chronic spontaneous urticaria (CSU) is still perceived as an uncontrollable and difficult to manage disease. The perception of the patient is that his/her condition is not well understood and that is suffering from a disorder with hidden causes that doctors are not able to tackle. Sometimes patients go through a number of clinicians until they found some CSU expert who is familiar with the disease. It is surprising that myths and believes with no scientific support still persist. Guidelines are not widely implemented, and recent tools to assess severity are infrequently used. European and American recent guidelines do not agree in several key points related to diagnosis and treatment, which further contributes to confusion. With the aim to clarify some aspects of the CSU picture, a group of allergists and dermatologists from the Spanish Dermatology and Allergy societies developed a Frequent Asked Questions leaflet that could facilitate physicians work in daily practice and contribute to a better knowledge of common clinical scenarios related to patients with CSU.

show abstract

“…Our review is intended to provide a comprehensive, critical, and rigorous synthesis of this body of evidence and to provide an informed opinion on the use of omalizumab across the diverse patient phenotypes affected by CIU/CSU. As a systematic review, it extends and updates the clinical and product reviews and summaries on omalizumab in CIU/CSU published to date [27][28][29][30][31][32][33][34][35][36], and provides guidance to clinicians.…”

Section: Introductionmentioning

confidence: 90%

Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of ‘real-world’ evidence

Bernstein

Kavati

Tharp

et al. 2018

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

Chronic idiopathic/spontaneous urticaria (CIU/CSU) is a dermatological condition characterized by itchy wheals and/or angioedema of continuous or intermittent duration of ≥6 weeks with a high burden of disease and impact on quality of life. Omalizumab is a recombinant humanized monoclonal antibody that inhibits the binding of IgE to high affinity receptors, and is approved for the CIU/CSU indication. The objective of this systematic review was to evaluate and synthesize the evidence on the real-world effectiveness of omalizumab in CIU/CSU in daily clinical practice. Areas covered: This review of 84 observational effectiveness studies covers treatments (dosing, medication use), clinical outcomes (treatment response, disease activity, quality of life), and safety. Expert opinion: The clinical outcomes observed across studies underscore the real-world effectiveness of omalizumab in the management of CIU/CSU. Continued treatment may assist patients showing an initial response to achieve a complete treatment response. Response rates are aligned with observed changes in disease activity, symptom experience, and quality of life, and this across subtypes of CIU/CSU. The positive therapeutic profile is complemented by a positive safety profile. The real-world evidence summarized here points convincingly at the high degree of effectiveness of omalizumab in the treatment of CIU/CSU in daily clinical practice.

show abstract

Omalizumab for Chronic Urticaria: A Case Series and Overview of the Literature

Cited by 42 publications

References 29 publications

Treatment of Severe Cold Contact Urticaria with Omalizumab: Case Reports

Treatment of Severe Cold Contact Urticaria with Omalizumab: Case Reports

Management of urticaria: not too complicated, not too simple

Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of ‘real-world’ evidence

Contact Info

Product

Resources

About